Every 10-Q that INmune Bio Inc. (INMB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INMB filings page.
INmune Bio Inc. reports that it remains a clinical-stage company with no product revenue and a net loss of $6.7 million for the six months ended June 30, 2026, a significant improvement from a $34.2 million loss a year earlier, largely due to lower Alzheimer’s program spend and the absence of a prior-year $16.5 million impairment.
Cash and cash equivalents were $18.4 million at June 30, 2026, down from $24.8 million, with $6.6 million used in operating activities in the first half. Management states that existing cash and projected operating needs create substantial doubt about the company’s ability to continue as a going concern for one year after issuance.
The lead program is CORDStrom for recessive dystrophic epidermolysis bullosa, which has completed a pivotal randomized cross-over trial. The company plans to file a Marketing Authorization Application in the UK by late 2026, an EU filing in early 2027, then a BLA with the FDA. INmune Bio also highlights $4.4 million in R&D tax rebates received in the first half and continued access to a $65 million at-the-market equity facility, of which only a small portion has been used.
INmune Bio Inc. reported a net loss of $5.4 million for the three months ended March 31, 2026, narrower than the $9.7 million loss a year earlier, as research and development spending fell to $3.6 million from $7.6 million after completing its Alzheimer’s Phase 2 trial.
The company had $21.4 million in cash and cash equivalents and used $3.4 million in operating cash during the quarter. Management concluded that these resources are projected to be insufficient to fund operations for one year after the statements are issued, raising substantial doubt about its ability to continue as a going concern.
INmune Bio is a clinical-stage biotech focused on reprogramming the innate immune system, with lead program CORDStrom for recessive dystrophic epidermolysis bullosa. The company is preparing marketing applications in the UK, EU and plans a U.S. BLA targeted for 2026, while also expanding long-term umbilical cord tissue supply through an amended Anthony Nolan agreement.
INmune Bio (INMB) reported third‑quarter 2025 results with a net loss of $6,472,000 and other income of $961,000, driven largely by interest income and a $0.6M vendor settlement gain. Cash and cash equivalents were $27,734,000 at September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern based on projected operating needs versus available liquidity.
Operating expenses fell year over year as research and development declined to $4,887,000 on trial completion and staff reductions, while general and administrative was $2,546,000. For the nine months, the company recorded a $16,514,000 impairment to XPro in‑process R&D after its Phase 2 did not meet primary and key secondary endpoints, and it halted immediate plans to develop XPro while seeking a partner. The company advanced CORDStrom for RDEB, with FDA Rare Pediatric Disease and Orphan Drug Designations, and intends to pursue a BLA. Shares outstanding were 26,585,258 as of October 30, 2025.